Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 4, 2025 • 9:31 AM ET

Date/Time Source News Release
05/30/2025 07:17 AM EDT GlobeNewswire Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
05/19/2025 08:00 AM EDT GlobeNewswire Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
05/01/2025 07:34 AM EDT GlobeNewswire Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
04/28/2025 07:41 AM EDT GlobeNewswire Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®(TM)
04/02/2025 08:17 AM EDT GlobeNewswire Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
03/18/2025 07:22 AM EDT GlobeNewswire Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
02/14/2025 05:06 PM EST GlobeNewswire Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
12/12/2024 08:15 AM EST Business Wire Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
11/19/2024 07:17 AM EST GlobeNewswire Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
11/14/2024 07:15 AM EST GlobeNewswire Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Page

Additional News

As of June 4, 2025 • 9:31 AM ET

Date/Time Source News Release
05/02/2025 09:40 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Highlights ADI-100 Developments in Weekly Update Featuring Leadership Team
04/17/2025 10:15 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) to Host Mayo Clinic's Dr. Charles Howe in May 2 Update on ADI-100(TM) Preclinical Study
04/16/2025 09:15 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Gains IRB Approval for Endometriosis Diagnostic Study
04/14/2025 09:35 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Advances Autoimmune Therapy Following Positive Mayo Clinic Study on ADI-100
04/11/2025 08:45 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance and Previews Strategic Updates
04/09/2025 09:35 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance, Hearing Canceled
04/02/2025 09:15 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) to Host Appili CEO in April 4 Update Focused on Infectious Disease Innovation
03/28/2025 09:35 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Highlights CaSe Platform Acquisition in Weekly Update Focused on Early Cancer Detection
03/24/2025 09:45 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Acquires Patents for DNA Damage Detection in Cancer Prevention
03/18/2025 09:20 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Provides Update on Appili Therapeutics Acquisition and Federal Funding Applications
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.